Acerta Pharma BV
🇳🇱Netherlands
Clinical Trials
107
Active:77
Completed:22
Trial Phases
4 Phases
Phase 1:76
Phase 2:13
Phase 3:10
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (101 trials with phase data)• Click on a phase to view related trials
Phase 1
76 (75.2%)Phase 2
13 (12.9%)Phase 3
10 (9.9%)Not Applicable
2 (2.0%)A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 30
- Registration Number
- NCT05140096
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 72
- Registration Number
- NCT04914936
A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 12
- Registration Number
- NCT04905043
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 59
- Registration Number
- NCT04901923
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Microtracer [14C]ACP-196
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 14
- Registration Number
- NCT04898101
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
No news found